Management of gastrointestinal motility disorders. A practical guide to drug selection and appropriate ancillary measures

Drugs

Volumn 52, Issue 4, 1996, Pages 494-506

  Malagelada, Juan R ^a   Distrutti, Eleonora ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8,9 ANHYDRO N ETHYLNORERYTHROMYCIN A 6,9 HEMIACETAL; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; ANTIPARKINSON AGENT; CALCIUM ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; CLEBOPRIDE; CLONIDINE; DOMPERIDONE; ERYTHROMYCIN; FEDOTOZINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; INDOMETACIN; ISONIAZID; ISOSORBIDE DINITRATE; METOCLOPRAMIDE; MISOPROSTOL; MUSCARINIC RECEPTOR BLOCKING AGENT; OCTREOTIDE; OPIATE; PHENOTHIAZINE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RANITIDINE; SULPIRIDE; TRICYCLIC ANTIDEPRESSANT AGENT;

DIET THERAPY; DISEASE SEVERITY; DRUG USE; DYSTONIA; ESOPHAGUS DISEASE; EXTRAPYRAMIDAL SYNDROME; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; HUMAN; INTESTINE PSEUDOOBSTRUCTION; LIFE EXPECTANCY; LIFESTYLE; MOTOR DYSFUNCTION; NONHUMAN; NUTRITION; ORAL DRUG ADMINISTRATION; PARENTERAL NUTRITION; PATHOPHYSIOLOGY; PATIENT CARE; PROGNOSIS; QUALITY OF LIFE; RECTAL DRUG ADMINISTRATION; REVIEW; STOMACH PARESIS; SUBLINGUAL DRUG ADMINISTRATION; SURVIVAL; SYMPTOMATOLOGY; THORAX PAIN; TREATMENT PLANNING;

EID: 0029820781     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652040-00003     Document Type: Review

References (96)

1. Janssens J, Vantrappen G, Ghillebert G. 24-hour recording of esophageal pressure and pH in patients with noncardiac chest pain. Gastroenterology 1986; 90: 1978-84
2. Peters L, Maas L, Petty D, et al. Spontaneous noncardiac chest pain: evaluation by 24-hour ambulatory esophageal motility and pH monitoring. Gastroenterology 1988; 94: 878-86
3. Breumelhof R, Nadorp JHSM, Akkermans LMA, et al. Analysis of 24-hour esophageal pressure and pH data in unselected patients with noncardiac chest pain. Gastroenterology 1990; 99: 1257-64
4. Soffer EE, Scalabrini P, Wingate DL. Spontaneous noncardiac chest pain: value of ambulatory esophageal pH and motility monitoring. Dig Dis Sci 1989; 34: 1651-5
5. Schindlbeck NE, Klauser AG, Voderholzer WA, et al. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med 1995; 155: 1808-12
6. Klinkenberg-Knol EC, Festen HP, Meuwissen SG. Pharmacological management of gastro-oesophageal reflux disease. Drugs 1995; 49: 695-710
7. Vantrappen G, Janssens J, Ghillebert G. The irritable oesophagus - a frequent cause of angina-like pain. Lancet 1987; 1: 1232-4
8. Allen M, Mellow M, Robinson MG, et al. Comparison of calcium channel blocking agents and an anticholinergic agent on oesophageal function. Aliment Pharmacol Ther 1987; 1: 153-9
9. Konrad-Dalhoff I, Baunack AR, Ramsch KD, et al. Effect of calcium antagonists nifedipine, nitrendipine, nimodipine and nisoldipine on oesophageal motility in man. Eur J Clin Pharmacol 1991; 41: 313-6
10. Cattau Jr EL, Castell DO, Johnson DA, et al. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol 1991; 86: 272-6
11. Triadafilopoulos G, Aaronson M, Sackel S, et al. Medical treatment of esophageal achalasia: double-blind crossover study with oral nifedipine, verapamil and placebo. Dig Dis Sci 1991; 36: 260-7
12. Bortolotti M, Coccia G, Brunelli F, et al. Isosorbide dinitrate or nifedipine: which is preferable in the medical therapy of achalasia? Ital J Gastroenterol 1994; 26: 379-82
13. Achem-Karam SR, Kolts BE. Current medical therapy for esophageal motility disorders. Am J Med 1992; 92: 98S-105S
14. Peterson WG, Selucky M, Hynna-Liepert TT. Effect of intraesophageal location and muscarinic blockade on balloon distension-induced chest pain. Dig Dis Sci 1991; 36: 282-8
15. Bassotti G, Gaburri M, Imbimbo PB, et al. Manometric evaluation of cimetropium bromide activity in patients with nut-cracker oesophagus. Scand J Gastroenterol 1988; 23: 1079-84
16. Marzio L, Pieramico O, Neri M, et al. Comparative study of the effects of cimetropium bromide and atropine on human esophageal motor functions. Digestion 1989; 44: 117-23
17. Marzio L, Grossi L, DeLaurentis MF, et al. Effect of cimetropium bromide on esophageal motility and transit in patients affected by primary achalasia. Dig Dis Sci 1994; 39: 1389-94
18. Corazziari E, Bontempo I, Anzini F. Effects of cisapride on distal esophageal motility in humans. Dig Dis Sci 1989; 34: 1600-1605
19. Robertson CS, Evans DF, Ledingham SJ, et al. Cisapride in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 181-90
20. Bost R, Hostein J, Carpentier P, et al. Effects of cisapride on oesophageal motility patterns in systemic sclerosis. Eur J Gastroenterol Hepatol 1992; 4: 323-8
21. Wienbeck M, Li Q. Cisapride on gastro-oesophageal reflux disease: effects on oesophageal motility and intra-oesophageal pH. Scand J Gastroenterol 1989; 24 (Suppl. 165): 13-8
22. Achem-Karam SR, Funakoshi A, Vinik AI, et al. Plasma moulin concentration and interdigestive migrating motor complex in diabetic gastroparesis: effect of metoclopramide. Gastroenterology 1985; 88: 492-9
23. McCallum RW, Valenzuela GA, Polepalle S, et al. Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. J Pharmacol Exp Ther 1991; 258: 136-42
24. McHugh S, Lico S, Diamant NE. Cisapride vs metoclopramide: an acute study in diabetic gastroparesis. Dig Dis Sci 1992; 37: 997-1001
25. Nelson KA, Walsh TD. Metoclopramide in anorexia caused by cancer-associated dyspepsia syndrome (CADS). J Palliat Care 1993; 9: 14-8
26. Drenth JP, Engels LG. Diabetic gastroparesis: a critical reappraisal of new treatment strategies. Drugs 1992; 44: 537-53
27. Takeda K, Taniyama K, Kuno T, et al. Clebopride enhances contractility of the guinea pig stomach by blocking peripheral D2 dopamine receptor and alpha-2 adrenoceptors. J Pharmacol Exp Ther 1991; 257: 806-11
28. Bleiberg H, Piccart M, Lips S, et al. A phase I trial of a new antiemetic drug - clebopride malate - in cisplatinum-treated patients. Ann Oncol 1992; 3: 141-3
29. Sabbatini F, Minieri M, Manzi G, et al. Clinical efficacy anf safety of cisapride and clebopride in the managment of chronic functional dyspepsia: a double-blind, randomized study. Ital J Gastroenterol 1991; 23: 1-4
30. Arienti V, Corazza GR, Sorge M, et al. The effects of levosulpiride on gastric and gallbladder emptying in functional dyspepsia. Aliment Pharmacol Ther 1994; 8: 631-8
31. Horowitz M, Harding PE, Chatterton BE, et al. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985; 30: 1-9
32. Feldman M, Smith HJ. Effect of cisapride on gastric emptying of indigestible solids in patients with gastroparesis diabeticorum: a comparison with metoclopramide and placebo. Gastroenterology 1987; 92: 171-4
33. Camilleri M, Malagelada J-R, Abell TL, et al. Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology 1989; 96: 704-12
34. Fraser R, Horowitz M, Maddox A, et al. Dual effects of cisapride on gastric emptying and antropyloroduodenal motility. Am J Physiol 1993; 264: G195-201
35. Kawagishi T, Nishizawa Y, Okuno Y, et al. Effect of cisapride on gastric emptying of indigestible solids and plasma motilin concentration in diabetic autonomic neuropathy. Am J Gastroenterol 1993; 88: 933-8
36. Richards RD, Valenzuela GA, Davenport KG, et al. Objective and subjective results of a randomized, double-blind, placebo-controlled trial using cisapride to treat gastroparesis. Dig Dis Sci 1993; 38: 811-6
37. Gullikson GW, Virina MA, Loeffler R, et al. Alpha 2-adrenergic model of gastroparesis: validation with renzapride, a stimulatory of motility. Am J Physiol 1991; 261: G426-32
38. Mackie AD, Ferrington C, Cowan S, et al. The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis. Aliment Pharmacol Ther 1991; 5: 135-42
39. Abell TL, Camilleri M, DiMagno EP, et al. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci 1991; 36: 616-20
40. Corinaldesi R, Stanghellini V, Tosetti C, et al. The effect of different dosage schedules of cisapride on gastric emptying in idiopathic gastroparesis. Eur J Clin Pharmacol 1993; 44: 429-32
41. Dworkin BM, Rosenthal WS, Casellas AR, et al. Open label study of long-term effectiveness of cisapride in patients with idiopathic gastroparesis. Dig Dis Sci 1994; 39: 1395-8
42. Muller Lissner SA, Fraas C, Hartl A. Cisapride offsets dopamine-induced slowing of tasting gastric emptying. Dig Dis Sci 1986; 31: 807-10
43. Djaldetti R, Koren M, Ziv I, et al. Effect of cisapride on response fluctuations in Parkinson's disease. Mov Disord 1995; 10: 81-4
44. Bran S, Murray WA, Hirsch IB, et al. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995; 155: 765-8
45. Kendall BJ, McCallum RW. Gastroparesis and the current use of prokinetic drugs. Gastroenterologist 1993; 1: 107-14
46. Fiorucci S, Bosso R, Morelli A. Erythromycin stimulates gallbladder emptying and motilin release by an atropine sensitive pathway. Dig Dis Sci 1992; 37: 1678-83
47. Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med 1990; 322: 1028-31
48. Catnach SM, Fairclough PD. Erythromycin and the gut. Gut 1992; 33: 397-401
49. Nakamura T, Ishii M, Arai Y, et al. Effect of intravenous administration of EM523L on gastric emptying and plasma glucose levels after a meal in patients with diabetic gastroparesis; a pilot study. Clin Ther 1994; 16: 989-99
50. Rosa-e-Silva L, Troncon LE, Oliveira RB, et al. Treatment of diabetic gastroparesis with oral clonidine. Aliment Pharmacol Ther 1995; 9: 179-83
51. Fioramonti J, Soldani G, Houde C, et al. Effect of ranitidine and oxmetadine on gastrointestinal motility in conscious dog. Agents Actions 1984; 15: 260-3
52. Bortolotti M, Cucchiara S, Sarti P, et al. Interdigestive gastroduodenal motility in patients with ulcer-like dyspepsia: effect of ranitidine. Hepatogastroenterology 1992; 39: 31-3
53. Bortolotti M, Cucchiara S, Sarti P, et al. Comparison between the effects of neostigmine and ranitidine on interdigestive gastroduodenal motility of patients with gastroparesis. Digestion 1995; 56: 96-9
54. 2-antagonists modify gastric emptying in the rat. Br J Pharmacol 1982; 77: 443-8
55. Sasho S, Obase H, Ichikawa S, et al. Synthesis of 2-imidazo-lidinylidenepropanedinitrile derivatives as stimulators of gastrointestinal motility. J Med Chem 1993; 36: 572-9
56. McCallum RW, Polepalle SC, Schirmer B. Completion gastrec-tomy for refractory gastroparesis following surgery for peptic ulcer disease: long-term follow-up with subjective and objective parameters. Dig Dis Sci 1991; 36: 1556-61
57. Christensen J, Dent J, Malagelada J-R, et al. Pseudo-obstruction. Gastroenterol Int 1990; 3: 107-19
58. Pitt HA, Mann LL, Berquist WE, et al. Chronic intestinal pseudo-obstruction: management with total parenteral nutrition and a venting enterostomy. Arch Surg 1985; 120: 614-8
59. Vargas JH, Sachs P, Ament ME. Chronic intestinal pseudo-obstruction syndrome in pediatrics: results of a national survey by members of the North American Society of Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 1988; 7: 323-32
60. Warner E, Jeejeebhoy KN. Successful management of chronic intestinal pseudo-obstruction with home parenteral nutrition. J Parent Enter Nutr 1985; 9: 173-8
61. Moukarzel AA, Haddad I, Ament ME, et al. 230 patient years of experience with home long-term parenteral nutrition in childhood: natural history and life of central venous catheters. J Pediatr Surg 1994; 29: 1323-7
62. Roger R, Cerda J. The narcotic bowel syndrome. J Clin Gastroenterol 1989; 11: 132-5
63. Cappell MS, Simon T. Colonic toxicity of administered medications and chemicals. Am J Gastroenterol 1993; 88: 1684-9
64. Sandgren JE, McPhee MS, Greenberger NJ. Narcotic bowel syndrome treated with clonidine: resolution of abdominal pain and intestinal pseudo-obstruction. Ann Intern Med 1984; 101: 331-4
65. Sehang JC, Devroede G. Beneficial effects of naloxone in patients with intestinal pseudo-obstruction. Am J Gastroenterol 1985; 80: 407-11
66. Keshavarzian A, Isaacs P, McColl I, et al. Idiopathic intestinal pseudo-obstruction and contaminated small bowel syndrome-treatment with metronidazole, ileostomy, and indomethacin. Am J Gastroenterol 1983; 78: 562-5
67. Luderer JR, Deniers LM, Bonnem EM, et al. Elevated prostaglandin E in idiopathic intestinal pseudo-obstruction. N Engl J Med 1976; 295: 1179
68. Softer EE, Metcalf A, Launspach J. Misoprostol is effective treatment for patients with severe chronic constipation. Dig Dis Sci 1994; 39: 929-33
69. Roarty TP, Yeaton P, McCallum RW. High dose misoprostol in the successful treatment of acquired megacolon in a 23 year old man. Am J Gastroenterol 1994; 89: 1746
70. Casella F, Malagelada J-R. Diarrhea due to bacterial overgrowth and motility disorders. In: Winawer SJ, editor. Management of gastrointestinal disorders. New York: Raven Press, 1992; 15.1-18
71. McCallum RW. Cisapride: a new class of prokinetic agent. Am J Gastroenterol 1991; 86: 135-49
72. Camilleri M, Brown ML, Malagelada J-R. Impaired transit of chyme in chronic intestinal pseudo-obstruction: correction with cisapride. Gastroenterology 1986; 91: 619-26
73. Di Lorenzo C, Reddy SN, Villanueva-Meyer J, et al. Cisapride in children with chronic intestinal pseudoobstruction: an acute, double-blind, crossover, placebo-controlled trial. Gastroenterology 1991; 101: 1564-70
74. Stanghellini V, Corinaldesi R, Ghidini C, et al. Reversibility of gastrointestinal motor abnormalities in chronic intestinal pseudo-obstruction. Hepatogastroenterology 1992; 39: 34-8
75. Camilleri M, Balm RK, Zinsmeister AR. Influence of neurologic dysfunction on response to cisapride in adults with chronic intestinal pseudo-obstruction [abstract]. Gastroenterology 1993; 104: A486
76. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 37: 1265-82
77. Benson MJ, Roberts JP, Wingate DL. Cisapride cover enhances post-operative antral motility and hastens recovery from ileus [abstract]. Gastroenterology 1994; 106: A466
78. Wiseman LR, Faulds D. Cisapride: an updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47: 116-52
79. Hyman PE, Di Lorenzo C, McAdams L, et al. Predicting the clinical response to cisapride in children with chronic intestinal pseudo-obstruction. Am J Gastroenterol 1993; 88: 832-6
80. Camilleri M, Balm RK, Zinsmeister AR. Determinants of response to a prokinetic agent in neurophatic chronic intestinal motility. Gastroenterology 1994; 106: 916-23
81. Armstrong DN, Ballantyne GH, Modlin IM. Erythromycin for reflex ileus in Olgivie's syndrome. Lancet 1991; 337: 378
82. Miller SM, O'Dorisio TM, Thomas FB, et al. Erythromycin exerts a prokinetic effect in patients with chronic idiopathic intestinal pseudo-obstruction [abstract]. Gastroenterology 1990; 98: A375
83. Fiorucci S, Distrutti E, Gerli R, et al. Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is mantained medium term. Am J Gastroenterol 1994; 89: 550-5
84. Soudan HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991; 325: 1461-9
85. von der Ohe MR, Camilleri M, Thomforde GM, et al. Differential regional effects of octreotide on human gastrointestinal motor function. Gut 1995; 36: 743-8
86. Edmunds MC, Chen JD, Lin Z, et al. The effect of octreotide on postprandial antral motility in patients with idiopathic gastroparesis [abstract]. Gastroenterology 1994; 107: A1246
87. Di Lorenzo C, Flores AF, Rehm D, et al. Octreotide induces MMCs which persist after feeding in children with enteric neuromuscolar disease (END) [abstract]. Gastroenterology 1994; 107: A1246
88. Verne GN, Eaker EY, Hardy E, et al. Use of octreotide and gastrointestinal manometry in idiopathic chronic intestinal pseudo-obstruction [abstract]. Gastroenterology 1994; 106: A584
89. Stolk MFJ, van Erpecum KJ, Koppeschaar HPF, et al. Effect of octreotide on fasting gall bladder emptying, antroduodenal motility, and motilin release in acromegaly. Gut 1995; 36: 755-60
90. Haruma K, Wiste JA, Camilleri M. Effect of octreotide on gastrointestinal pressure profiles in health and in functional and organic gastrointestinal disorders. Gut 1994; 35: 1064-9
91. Freilich HS, Chopra S, Gilliam JI. Acute colonic pseudo-obstruction or Olgivie's syndrome: report of two cases treated with colonscopic decompression and review of the literature. J Clin Gastroenterol 1986; 8: 457-60
92. Nano D, Prindiville T, Pauly M, et al. Colonscopic therapy of acute pseudo-obstruction on the colon. Am J Gastroenterol 1987; 82: 145-8
93. Murr MM, Sarr MG, Camilleri M. The surgeon's role in the treatment of chronic intestinal pseudoobstruction. Am J Gastroenterol 1995; 90: 2147-51
94. Mughal MM, Irving MH. Treatment of end stage chronic intestinal pseudoobstruction by subtotal enterectomy and home parenteral nutrition. Gut 1988; 24: 1613-7
95. Mansell PI, Tattersall RB, Balsitis M. Megaduodenum due to hollow visceral myopathy successfully managed by duodenoplasty and feeding jejunostomy. Gut 1991; 32: 334-7
96. Todo S, Tzakis A, Reyes J, et al. Intestinal transplantation at the University of Pittsburgh. Transplant Proc 1994; 26: 1409-10